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Abstract 
Background: The SAMe-TT2R2 (sex female, age, medical history, treatment, tobacco use, race) 
score was developed in patients with atrial fibrillation (AF) on warfarin. The present study aimed to 
1) compare the anticoagulation quality and management of AF patients treated with warfarin with those 
on acenocoumarol and 2) optimize the SAMe-TT2R2 score to detect AF patients at high risk of unstable 
anticoagulation with acenocoumarol and warfarin. 
Methods: In a single-center retrospective study, 320 patients with AF, including 15 (5%) after valve re-
placement, aged 40–82 (median 70) years, including 203 (63%) receiving acenocoumarol and 117 (37%)  
treated with warfarin, were studied. The SAMe-TT2R2 score was modified based on the candidate factors 
retrieved from univariate regression and assessed using the receiver operating curves (ROC). 
Results: A median SAMe-TT2R2 score was 2 (1–3). Proportions of patients with ≥ 2 points and 0–1 
points in the SAMe-TT2R2 score who had the time in therapeutic range (TTR) ≤ 70% were similar (61 
[67%] vs. 63 [56%], p = 0.11). A modified score, involving medical history (myocardial infarction [MI] 
and chronic obstructive pulmonary disease [COPD], 1 point), statin treatment (1 point) and tobacco use 
(2 points) had a higher area under the curve (AUC) in patients on acenocoumarol compared to SAMe-
TT2R2 (0.66; 95% confidence interval 0.58–0.73 vs. 0.56; 0.48–0.64, p = 0.042); ≥ 1 point indicated TTR  
> 70% with a sensitivity and specificity of 61% and 63%, respectively. 
Conclusions: The SAMe-TT2R2 score is less effective in predicting unstable anticoagulation with 
acenocoumarol versus warfarin. Adding statin use and highlighting COPD and previous MI increases 
a predictive value of this score for acenocoumarol.  (Cardiol J 2017; 24, 5: 477–483)
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Introduction
The prevalence of atrial fibrillation (AF) has 
quadrupled over the last 50 years [1]. Although 
non-vitamin K antagonists have been introduced 
in therapy of AF, vitamin K antagonists (VKA) 
remained the only treatment with established 
safety in valvular AF [2]. Quality of anticoagula-
tion with VKA, assessed by the time in therapeutic 
range (TTR), is closely associated with the risk of 
stroke [3, 4]. Recently, several factors have been 
incorporated by Apostolakis et al. [5] into a clinical 
prediction scheme with the acronym SAMe-TT2R2 
(sex female, age > 60 years, medical history [more 
than two comorbidities], treatment [interacting 
drugs, e.g. amiodarone for rhythm control], tobacco 
use [doubled], race [doubled]). 
The anticoagulants assessed by Apostolakis 
et al. [5] have been referred to as VKA; however, 
the population included in the AFFIRM (The Atrial 
Fibrillation Follow-up Investigation of Rhythm 
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farin [6]. The SAMe-TT2R2 score has been dem-
onstrated to have a modest ability of predicting 
stable anticoagulation control in patients treated 
with acenocoumarol [7], but there are no reports 
on the comparison of clinical utility of SAMe-TT2R2 
for warfarin and acenocoumarol. The differences 
observed in anticoagulation control dependent on 
the type of VKA may result from a shorter half-life 
of acenocoumarol compared to warfarin [8]. Apart 
from the pharmacokinetic profile, it has been shown 
that carriers of variant alleles for cytochrome P 
type 2C9 (CYP2C9) and gamma-glutamyl carboxy-
lase genes required a lower dose of warfarin as 
compared with non-carriers; the effects of those 
polymorphisms have been absent with regard to 
acenocoumarol dose [9]. Arterial hypertension, 
use of statins and aspirin as well as older age were 
identified by Undas et al. [10] as the clinical factors 
responsible for improved anticoagulation control 
after switching from acenocoumarol to warfarin. 
Those observations might be especially interes-
ting in regard to differences in utility of SAMe- 
-TT2R2 for predicting stability of anticoagulation on 
warfarin and acenocoumarol, as the score is based 
on common clinical factors. 
We aimed to: 1) compare the anticoagulation 
quality and management of AF patients treated 
with warfarin with those on acenocoumarol and 
2) optimize the SAMe-TT2R2 score to detect AF 
patients at high risk of unstable anticoagulation 
with acenocoumarol and warfarin. 
Methods
Study design
This single-center retrospective study in-
cluded 320 consecutive patients with documented 
AF, from the databases who were referred to the 
John Paul II Hospital, Krakow, Poland between 
2010 and 2012. All patients were on oral antico-
agulation with VKA for at least 6 months prior 
to enrolment. Paroxysmal AF, persistent AF and 
permanent AF were defined according to the Eu-
ropean Society of Cardiology guidelines [11]. The 
exclusion criteria were: signs of acute infection 
and C-reactive protein ≥ 10 mg/L, acute coronary 
syndrome within the preceding 12 months being 
treated with dual antiplatelet therapy, hepatic 
injury (alanine aminotransferase ≥ 1.5 times the 
upper limit of normal), chronic kidney disease 
stage 4 or more or known malignancy. The study 
was approved by the Ethical Committee of the 
Jagiellonian University. All participants gave 
informed consent.
Data on demographic characteristics, cardio-
vascular risk factors, comorbidities, prior valvular 
surgery and treatment were collected by the 
recruiting physician. Obesity was defined as body 
mass index ≥ 30 kg/m2. Arterial hypertension was 
diagnosed based on a history of hypertension (con-
sistent blood pressure ≥ 140/90 mm Hg). Diabetes 
mellitus was defined as according to the American 
Diabetic Association criteria [12]. Coronary artery 
disease was diagnosed based on positive results 
of cardiac stress tests, cardiac catheterisation, or 
coronary computed tomography angiography. Myo-
cardial infarction (MI) was recognized according to 
the guidelines [13]. Heart failure was defined as 
the presence of relevant symptoms and signs and 
left ventricular ejection fraction ≤ 40%. Ischemic 
stroke prior to the enrollment was diagnosed based 
on the symptoms and positive finding of brain non-
contrast-enhanced computed tomography [14]. 
Chronic obstructive pulmonary disease (COPD) 
was diagnosed based on the signs and symptoms 
and results of spirometry. Chronic kidney disease 
was defined according to the guidelines [15]. 
TTR during VKA treatment was calculated with 
Rosendaal’s method [16]. Stable anticoagulation 
was defined as having the TTR of ≥ 70% [17]. The 
value of ≥ 2 points in SAMe-TT2R2 score (sex fe-
male, age > 60 years, medical history [more than 
two comorbidities], treatment [interacting drugs, 
e.g. amiodarone for rhythm control], tobacco use 
[doubled], race [doubled]) indicated the risk of 
unstable anticoagulation [5]. The CHA2DS2-VASc 
(cardiac failure, hypertension, age > 75 years, 
diabetes, stroke, vascular disease, age 65–74 and 
sex) score was used to assess the risk of stroke.
Statistical analysis
Categorical variables were presented as num-
bers and percentages. Continuous variables were 
expressed as mean ± standard deviation (SD) or 
median and interquartile range. Normality was 
assessed by the Shapiro-Wilk test. Equality of 
variance was assessed using the Levene’s test. 
Differences between groups were compared us-
ing the Student’s or the Welch’s t-test depending 
on equality of variance for normally distributed 
variables. The Mann-Whitney U test was used 
for non-normally distributed continuous vari-
ables. Categorical variables were compared by the 
Fisher’s exact test for 2 × 2 contingency tables and 
Pearson’s c2 test for other tables. 
To assess the predictive ability of identifying 
the unstable patients with the SAMe-TT2R2 score, 
compared herein was the percentage of patients with 
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TTR ≤ 70% among patients with SAMe-TT2R2 ≥ 2 
vs. 0–1. The univariate logistic regression was per-
formed to calculate the odds ratio (OR) and 95% con-
fidence interval (95% CI) of achieving TTR > 70% 
for the following factors. Covariates associated 
with TTR at levels of 0.1 in univariate analysis 
served as candidate factors to build the modified 
model, where each factor was given 1 or 2 points. 
The modified models were further tested in binary 
logistic regression models using a TTR cut-off at 
70%. The predictive ability of the modified score 
was compared with SAMe-TT2R2 score using area 
under the receiver operating curve (AUC). The 
sensitivity and specificity were calculated. P-values 
< 0.05 were considered statistically significant. 
The study was powered to have a 80% chance of 
detecting a 2–4% TTR difference between groups 
stratified by SAMe-TT2R2 score of 0–1, 2–3 and 
≥ 4 using a p-value of 0.05. In order to demonstrate 
such a difference or greater, 102 patients were 
required in each group. All calculations were done 
with JMP®, Version 9.0.0 SAS Institute Inc., Cary, 
NC, 1989–2007.
Results
The final analysis included 320 patients, 203 
(63%) receiving acenocoumarol and 117 (37%) 
treated with warfarin. There were 305 patients 
with non-valvular AF, 11 (3%) subjects after mitral 
valve replacement, 3 (1%) following aortic valve 
replacement and 1 patient who underwent con-
comitant mitral and aortic valve replacement. The 
median age was 70 (minimum 46, maximum 89). 
The majority of the patients studied represented 
overweight women with permanent AF at high risk 
of ischemic stroke in CHA2DS2-VASc (Table 1). 
Patients treated with acenocoumarol were slightly 
younger, less frequently smoked cigarettes and 
were diagnosed with COPD compared to these 
receiving warfarin (Table 1). 
SAMe-TT2R2 
A median SAMe-TT2R2 score was 2 (1–3). 
Ninety one (45%) patients on acenocoumarol and 
77 (66%) on warfarin had SAMe-TT2R2 ≥ 2 (p = 
= 0.0003). The median TTR was 66 (58–75.5)% with 
no differences related to the type of VKA. Median 
TTR of patients with SAMe-TT2R2 ≥ 2 (n = 186, 
52%) was lower by 9.6% compared to those with 
SAMe-TT2R2 0–1 (64 [57–74]% vs. 70 [60–78]%, 
p = 0.002). There was a progressive decline 
in median TTR from the score of 0–1 to ≥ 4 in 
SAMe-TT2R2 score in the whole cohort of patients 
(70 [60–78]% vs. 65 [57–75]% vs. 61 [54.5–70]%, 
p = 0.007). The same was true for the patients 
treated with acenocoumarol (69 [59–77.5]% vs. 65 
[57–75]% vs. 55.5 [45.75–61.75]%, p = 0.009) and 
warfarin (71.5 [63.25–79]% vs. 63 [56.5–73]% vs. 
63.5 [58.25–72.25]%, p = 0.05) (Fig. 1). 
124 patients (39%) had TTR > 70%. Among 
168 (52%) patients with SAMe-TT2R2 ≥ 2 there 
were 115 (68%) individuals with TTR ≤ 70%. 
Among patients treated with acenocoumarol, there 
was a similar proportion of patients with TTR 
≤ 70% among those SAMe-TT2R2 ≥ 2 points as well 
as 0–1 points (61 [67]% vs. 63 [56]%, p = 0.1). In 
contrast, taking into consideration only warfarin-
treated patients, there were more subjects with 
TTR ≤ 70% among those with SAMe-TT2R2 ≥ 2 
points in comparison to 0–1 points (54 [70]% vs. 
18 [45]%, p = 0.01).
Modified SAMe-TT2R2
The following candidate factors found in the 
univariate regression analysis for TTR > 70% 
(Table 2) were included in the modified score 
for acenocoumarol-treated patients: medical his-
tory (MI — 1 point; COPD — 1 point), treatment 
(statins — 1 point), tobacco use (2 points). In 
acenocoumarol-treated patients, the modified 
score predicting the TTR > 70% had increased 
AUC compared to the SAMeTT2R2 (0.66; 95% CI 
0.58–0.73 vs. 0.56; 95% CI 0.48–0.64, p = 0.04). 
The score of ≥ 1 point was associated with a TTR 
> 70% with a sensitivity and specificity of 61% 
and 63%, respectively. In the warfarin-treated 
patients, the AUC of identifying the TTR > 70% 
by the modified model was comparable with SAMe- 
-TT2R2 (AUC 0.61; 95% CI 0.51–0.71 vs. 0.65; 95% 
CI 0.55–0.75, p = 0.3). 
Discussion
According to the present research of avail-
able literature, this study is the first to compare 
the predictive ability of SAMe-TT2R2 score in AF 
patients treated with acenocoumarol versus war-
farin on a long-term basis. This study showed that 
common and clinical risk factors incorporated in the 
SAMe-TT2R2 score are less effective in predicting 
unstable anticoagulation in AF patients on aceno-
coumarol as compared to warfarin. The modified 
score highlights the impact of statins, previous MI 
and COPD on the quality of acenocoumarol treat-
ment in patients with AF.
Previously, Roldan et al. [18] validated the 
clinical value of the SAMe-TT2R2 score in a prospec-
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tive “real-world” cohort of 459 patients initiating 
oral anticoagulation with acenocoumarol. In a latter 
study patients with less than 2 points in SAMe- 
-TT2R2 score had TTR lower by 6% than those with 
more than 2 points, indicated that the score proper-
ly identified the individuals on acenocoumarol [18]. 
Table 1. Baseline characteristics of patients with atrial fibrillation (AF) treated with acenocoumarol 
and warfarin.
Variable Acenocoumarol 
(n = 203, 63%)
Warfarin 
(n = 117, 37%)
P
Demographic characteristics:
Male 89 (44%) 53 (45%) 0.8
Age [years] 69 (62–73) 72 (65–78) 0.006
BMI [kg/m2] 28 (24.6–32.6) 27.25 (24.5–31) 0.4
Tobacco use 23 (11) 58 (50) < 0.001
Atrial fibrillation — type:
Permanent 91 (44%) 54 (46%) 0.2
Persistent 55 (27%) 40 (34%)
Paroxysmal 57 (28%) 23 (20%)
Time since AF diagnosis [years] 5 (3-9) 4.0 (3–10) 0.8
Comorbidities:
Coronary artery disease 60 (30%) 20 (17%) 0.02
Myocardial infarction 35 (17%) 19 (16%) 0.9
Peripheral artery disease 8 (4%) 28 (24%) < 0.001
Arterial hypertension 118 (58%) 62 (53%) 0.4
Heart failure 50 (25%) 19 (16%) 0.09
Stroke 25 (12%) 20 (17%) 0.2
COPD 21 (10%) 34 (29%) < 0.001
Diabetes mellitus type 2 34 (17%) 21 (18%) 0.9
Chronic kidney disease 25 (12%) 22 (19%) 0.1
Medication:
VKA weekly dose [mg/week] 32.0 (23.0–42.0) 35.0 (21.0–48.0) –
TTR [%] 66.5 ± 14.3 66.7 ± 13.3 0.09
Acetylsalicylic acid 60 (30%) 20 (17%) 0.02
Clopidogrel 10 (5%) 3 (3%) 0.4
Beta-blocker 113 (56%) 57 (49%) 0.2
ACEI 76 (37%) 40 (34%) 0.6
Statin 83 (41%) 44 (38%) 0.6
Amiodarone 26 (13%) 9 (8%) 0.2
Digoxin 29 (14%) 15 (13%) 0.9
Scores:
SAMe-TT2R2 1 (1–2) 2 (1–3) < 0.001
SAMe-TT2R2 ≥ 2 38 (19%) 49 (42%) < 0.001
CHA2DS2-VASc 3 (2–4) 3 (2–4) 0.5
CHA2DS2-VASc ≥ 2 164 (81%) 97 (83%) 0.1
CHA2DS2-VASc = 1 29 (14%) 17 (14%) 0.6
CHA2DS2-VASc = 0 10 (5%) 3 (3%) 0.5
Data are given as number (percentage) or mean ± standard deviation or median (interquartile range). Results are presented as the p-value for 
Fisher’s exact test for categorical variables or t-Student’s test for normally distributed variables or Mann-Whitney’s test for other variables.
BMI — body mass index; COPD — chronic obstructive pulmonary disease; VKA — vitamin K antagonists; TTR — time in therapeutic range; 
ACEI — angiotensin converting enzyme inhibitor; SAMe-TT2R2 — sex female, age, medical history, treatment, tobacco use, race score; 
CHA2DS2-VASc — cardiac failure, hypertension, age  > 75 years, diabetes, stroke, vascular disease, age 65–74 and sex score
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Figure 1. Comparison of the median time in therapeutic 
range (TTR) between patients treated acenocoumarol 
and warfarin with 0–1, 2–3 and more than 4 points in 
SAMe-TT2R2 (sex, age < 60 years, more than two co-
morbidities, interacting drugs, tobacco and race) score. 
Vertical lines extend from the 25th to the 75th percentiles, 
with the horizontal lines in the middle at the median 
value. 
However, in a subsequent Spanish study involving 
1524 patients, among them approximately 95% on 
acenocoumarol, the discriminating capability of the 
SAMe-TT2R2 score was modest (AUC 0.59) and did 
not improve after adding new factors [7].
In this study the percentage of AF patients with 
TTR less than 70% was comparable among individu-
als with SAMe-TT2R2 over 2 points and 0–1 points. 
It suggested that SAMe-TT2R2 score was not able to 
identify the AF patients treated with acenocoumarol 
at risk of poor anticoagulation control using the 
TTR cut-off value of 70%. It seems that the clini-
cal factors predispose to unstable anticoagulation 
to a different extent during treatment with warfa-
rin and acenocoumarol. It was found that COPD, 
reported to coexist in a considerable percentage 
of AF patients (10%) [19], strongly contributed 
to the prediction of the anticoagulation stability. 
A potential factor which might explain the associa-
tion between COPD and stability of anticoagula-
tion with acenocoumarol is drug–drug interaction. 
Patients with COPD exacerbation commonly re-
ceive corticosteroids and macrolides or fluoroqui-
nolones [20], both interacting with the anticoagulant 
Table 2. Factors associated with time in therapeutic range (TTR) > 70% in patients on acenocoumarol.
Variable OR (95% CI) P
Demographic data:
Male gender 0.80 (0.45–1.41) 0.4
Age < 60 years 1.25 (0.60–2.56) 0.5
Tobacco use 0.13 (0.02–0.45) < 0.001
Comorbidities:
Arterial hypertension 0.92 (0.52–1.64) 0.8
Myocardial infarction 0.48 (0.20–1.06) 0.07
Peripheral artery disease 0.51 (0.07–2.28) 0.4
Heart failure 0.95 (0.49–1.82) 0.9
Stroke 1.53 (0.65–3.56) 0.3
COPD 0.07 (0.00–0.33) < 0.001
Diabetes mellitus type 2 1.12 (0.52–2.36) 0.8
Chronic kidney disease 0.57 (0.21–1.39) 0.2
Medication:
Acetylsalicylic acid 0.97 (0.52–1.79) 0.9
Clopidogrel 0.66 (0.14–2.45) 0.5
Beta-blockers 0.85 (0.48–1.50) 0.6
ACEI 0.79 (0.44–1.43) 0.4
Statin 0.53 (0.29–0.94) 0.031
Digoxin 1.13 (0.50–2.49) 0.8
Amiodarone 0.81 (0.33–1.88) 0.6
Data presented as the odds ratio (OR) and 95% confidence interval (CI) and p-value calculated using the logistic univariate regression analysis; 
COPD — chronic obstructive pulmonary disease; ACEI —  angiotensin-converting enzyme inhibitor
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treatment [21]. Here might be the point where the 
shorter half-live of acenocoumarol may not entirely 
justify but may exaggerate the effect of interact-
ing drugs on the acenocoumarol pharmacokinetics 
in comparison to warfarin.
The present study emphasised the role of the 
previous MI in maintaining stable anticoagulation. 
MI is an established risk factor for AF, with AF oc-
curring in 6% to 21% of patients following MI [22, 
23]. The poor TTR control was an independent 
predictor of major adverse cardiovascular events 
including MI in a cohort of 627 AF patients on VKA 
patients followed by Pastori et al. [24]. We assume 
that a decreased TTR prior to the MI may reflect 
the overall worse anticoagulation control observed 
in that subset of patients not only prior to but also 
following the MI. Mechanisms linking a history of 
MI with anticoagulation control need to be further 
investigated. 
Unexpectedly, in the present study, statin 
use has been identified to be a risk factor for un-
stable anticoagulation with acenocoumarol. Previ-
ously, statins have been associated with the 9% 
lower risk of bleeding during VKA therapy [25], 
which suggested beneficial influence of statins on 
the anticoagulation stability. Statins favourably 
modulate blood coagulation by exerting mild an-
ticoagulant and antiplatelet effects [26, 27]. The 
results of statins on blood clotting can also be 
observed in patients with AF [28]. In the context 
of VKA, drug–drug interactions may be however 
of key importance. Simvastatin has been found 
to reduce warfarin dose requirement by 29% in 
the CYP2C9*3 allele carriers compared with 5% 
in non-carriers [29]. This effect may predispose 
unstable anticoagulation in patients carrying the 
CYP2C9*3 allele that represent 12% of Poles [9]. 
Further investigations are required to establish 
mechanisms behind the relationship between statin 
use and stability of anticoagulation with warfarin 
and acenocoumarol. Other postulated beneficial 
influences of statin is slowing the evolution of AF 
and reducing inflammation and fibrosis [30].
Limitations of the study
Several study limitations should be acknowl-
edged. Firstly, baseline characteristics of the 
patients treated with acenocoumarol and warfarin 
in this study differed which could affect to some 
extent the differences observed in the discriminat-
ing ability of the scores. Secondly, the number of 
the studied patients was relatively low, although 
the study was sufficiently powered to show some 
intergroup differences. These findings cannot be 
reliably extrapolated to patients excluded from our 
analysis including those with advanced renal insuf-
ficiency or on dual antiplatelet therapy, as well as 
for predicting quality of anticoagulation with lower 
TTR out-offs [31]. Long-term follow-up to assess 
clinical impact of the scoring systems in terms of 
stroke and risk of bleeding was beyond the scope 
of the present study. 
Conclusions
1. The SAMe-TT2R2 score appears less effective 
in predicting unstable anticoagulation with 
acenocoumarol compared with warfarin. 
2. Adding the statin use and highlighting a role 
of COPD and previous MI in the modified score 
increase its predictive value for acenocoumarol.
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